Analysts estimate that Vir Biotechnology will report an earnings per share (EPS) of $-0.84. Vir Biotechnology bulls will hope to hear the company announce they've not only beaten that estimate, but ...

Vir Biotechnology, Inc.’s VIR share price has dipped by 5.45%, which has investors questioning if this is right time to buy.

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

Net Cash Consumed: $75.6 million in Q1 2025. Vir Biotechnology Inc (NASDAQ:VIR) successfully initiated the ECLIPSE Phase III registrational program for hepatitis delta virus, marking a significant ...

Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. "We successfully dosed the first patient in our ECLIPSE Phase 3 registrational program for hepatitis delta, a devastating disease with no ...

Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Wednesday, 2025-05-07. Here's what investors need to know before the announcement. Analysts estimate that Vir ...